HTG Molecular Diagnostics Inc Share Price Nasdaq
Equities
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
||
- | - |
|
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
Sales 2021 | 8.91M 0 699M | Sales 2022 | 6.37M 0 500M | Capitalization | 3.67M 0 288M |
---|---|---|---|---|---|
Net income 2021 | -17M - -1.33B | Net income 2022 | -21M - -1.65B | EV / Sales 2021 | 3.96 x |
Net cash position 2021 | 5.74M 0 450M | Net cash position 2022 | 3.41M 0 268M | EV / Sales 2022 | 0.04 x |
P/E ratio 2021 |
-2.19
x | P/E ratio 2022 |
-0.16
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98% |
Managers | Title | Age | Since |
---|---|---|---|
John Lubniewski
CEO | Chief Executive Officer | 60 | 31/03/11 |
Shaun McMeans
DFI | Director of Finance/CFO | 62 | 31/01/12 |
Chief Administrative Officer | 45 | 31/12/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 26/10/15 | |
Director/Board Member | 59 | 26/01/22 | |
Ann Hanham
CHM | Chairman | 71 | 28/08/16 |
1st Jan change | Capi. | |
---|---|---|
-33.70% | 14.31B | |
-57.92% | 2.1B | |
+22.96% | 1.95B | |
-23.94% | 1.28B | |
+19.67% | 1.21B | |
+1.10% | 779M | |
-37.32% | 748M | |
-37.03% | 720M | |
-29.95% | 596M |